Literature DB >> 31756687

Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response.

Chuan Liu1, Kui Liao2, Neil Gross3, Zhihai Wang1, Guojun Li3, Wenqi Zuo1, Shixun Zhong1, Zixin Zhang4, Hua Zhang5, Jianming Yang6, Guohua Hu7.   

Abstract

BACKGROUND: Radiotherapy is a central treatment option for hypopharyngeal squamous cell carcinoma, but the prognoses of patients treated with radiotherapy only are not satisfactory due to radioresistance. The underlying molecular mechanisms remain largely elusive, and mechanism-derived predictive markers of radioresistance are currently unavailable.
METHODS: In this study, we first established a specifically radioresistant FaDu cell line by repeated exposure to ionizing radiation with a total dose of 60 Gy (FaDu-RR). The validation of FaDu-RR cells was performed by clonogenic cell survival assay and cell proliferation assay. Microarrays and bioinformatics were analyzed to determine the differentially expressed mRNAs and their functions. DNA-repair capabilities were tested by cell cycle analysis and comet assay. The expressions of four key proteins in homologous recombination pathways, including BRCA1, BRCA2, RPA1, and Rad51, were detected both in FaDu-RR cells and radioresistant xenograft.
RESULTS: We established the specifically radioresistant FaDu cell line. Through microarrays and bioinformatics, homologous recombination pathways were suggested to play important roles in radioresistant mechanisms. High expression levels of key proteins in homologous recombination pathways were then detected both in FaDu-RR cells and radioresistant xenograft. Silencing RPA1 could reduce the radioresistance of FaDu-RR cells.
CONCLUSION: Our results provided strong evidence that homologous recombination enhances the radioresistance in hypopharyngeal carcinoma. Proteins in homologous recombination pathways may be potential biomarkers to predict hypopharyngeal carcinoma response to radiotherapy, establishing a basis for their utility in clinical practice.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  DNA damage response; Homologous recombination; Hypopharyngeal carcinoma; Radioresistance

Mesh:

Substances:

Year:  2019        PMID: 31756687     DOI: 10.1016/j.oraloncology.2019.104469

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  Suppressing UVRAG Induces Radiosensitivity by Triggering Lysosomal Membrane Permeabilization in Hypopharyngeal Squamous Cell Carcinoma.

Authors:  Jianwen Wang; Xuehai Wang; Kai Liu; Li Gu; Lei Yu; Li Han; Zhaojin Meng
Journal:  Onco Targets Ther       Date:  2020-10-13       Impact factor: 4.147

Review 2.  Biological Adaptations of Tumor Cells to Radiation Therapy.

Authors:  Angeles Carlos-Reyes; Marcos A Muñiz-Lino; Susana Romero-Garcia; César López-Camarillo; Olga N Hernández-de la Cruz
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

3.  Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation.

Authors:  Xuecen Wang; Zhirui Cao; Xin Yue; Tingyu Liu; Gesi Wen; Dongmei Jiang; Weijian Wu; Liyuan Le; Yan Wang; Chengtao Wang; Ziyang Wang; Meng Jin; Meiyan Zhu; Shasha He; Xiaoyue Zhang; Xianzhang Bu; Ran-Yi Liu; Zhenwei Peng; Yong Chen
Journal:  Mol Ther Oncolytics       Date:  2022-08-05       Impact factor: 6.311

4.  Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L.

Authors:  Jacqueline Nathansen; Vasyl Lukiyanchuk; Linda Hein; Maya-Isabel Stolte; Kerstin Borgmann; Steffen Löck; Ina Kurth; Michael Baumann; Mechthild Krause; Annett Linge; Anna Dubrovska
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

5.  PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.

Authors:  Chuan Liu; Neil Gross; Yanshi Li; Guojun Li; Zhihai Wang; Shixun Zhong; Yuncheng Li; Guohua Hu
Journal:  J Cell Mol Med       Date:  2020-01-19       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.